Placental ribonuclease inhibitor (PRI) is a member of a family of proteinaceous cytoplasmic RNase inhibitors that occur in many tissues and bind to both intracellular and extracellular RNases (summarized by Lee et al., 1988 [PubMed 3219362]). In addition to control of intracellular RNases, the inhibitor may have a role in the regulation of angiogenin (MIM 105850). Ribonuclease inhibitor, of 50,000 Da, binds to ribonucleases and holds them in a latent form. Since neutral and alkaline ribonucleases probably play a critical role in the turnover of RNA in eukaryotic cells, RNH may be essential for control of mRNA turnover\; the interaction of eukaryotic cells with ribonuclease may be reversible in vivo.[supplied by OMIM, Jul 2010].
Wang, Teferedegne, Shatzkes, Tu, Murata: "Data on the inhibition of RNase inhibitor activity by a monoclonal antibody as assessed by microfluidics-based RNA electrophoresis." in: Data in brief, Vol. 9, pp. 417-421, (2016) (PubMed).
Wang, Teferedegne, Shatzkes, Tu, Murata: "Endogenous RNase inhibitor contributes to stability of RNA in crude cell lysates: Applicability to RT-qPCR." in: Analytical biochemistry, Vol. 513, pp. 21-7, (2016) (PubMed).
Tang, Liu, Tian, Xu, Ren, Cui, Fan: "Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and metastasis in human colorectal cancer cells via PI3K/AKT pathway." in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, (2014) (PubMed).
Furia, Moscato, Calì, Pizzo, Confalone, Amoroso, Esposito, Nitsch, DAlessio: "The ribonuclease/angiogenin inhibitor is also present in mitochondria and nuclei." in: FEBS letters, Vol. 585, Issue 4, pp. 613-7, (2011) (PubMed).